Spears Abacus Advisors LLC Gilead Sciences, Inc. Transaction History

Spears Abacus Advisors LLC

  • $4.73 Billion
  • Q3 2024

A detailed history of Spears Abacus Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Spears Abacus Advisors LLC holds 4,891 shares of GILD stock, worth $446,792. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,891
Previous 4,225 15.76%
Holding current value
$446,792
Previous $289,000 41.52%
% of portfolio
0.01%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$66.59 - $83.99 $44,348 - $55,937
666 Added 15.76%
4,891 $409,000
Q1 2024

May 10, 2024
BUY
$71.58 - $87.29 $302,425 - $368,800
4,225 New
4,225 $309,000
Q4 2021

Feb 14, 2022
SELL
$64.88 - $73.64 $4.23 Million - $4.8 Million
-65,202 Closed
0 $0
Q3 2021

Nov 15, 2021
SELL
$67.69 - $73.03 $30,460 - $32,863
-450 Reduced 0.69%
65,202 $4.55 Million
Q2 2021

Aug 09, 2021
SELL
$63.47 - $69.35 $30,782 - $33,634
-485 Reduced 0.73%
65,652 $4.52 Million
Q1 2021

May 14, 2021
BUY
$60.0 - $68.46 $16,140 - $18,415
269 Added 0.41%
66,137 $4.27 Million
Q4 2020

Feb 12, 2021
SELL
$56.65 - $64.55 $140,605 - $160,213
-2,482 Reduced 3.63%
65,868 $3.84 Million
Q3 2020

Nov 16, 2020
BUY
$62.1 - $78.08 $49,680 - $62,464
800 Added 1.18%
68,350 $4.32 Million
Q2 2020

Aug 12, 2020
SELL
$72.34 - $84.0 $231,488 - $268,800
-3,200 Reduced 4.52%
67,550 $5.2 Million
Q1 2020

May 15, 2020
SELL
$62.63 - $80.22 $19.9 Million - $25.5 Million
-317,380 Reduced 81.77%
70,750 $5.29 Million
Q4 2019

Feb 14, 2020
BUY
$61.62 - $67.78 $86,268 - $94,892
1,400 Added 0.36%
388,130 $25.2 Million
Q3 2019

Nov 14, 2019
SELL
$62.51 - $69.0 $158,150 - $174,570
-2,530 Reduced 0.65%
386,730 $24.5 Million
Q2 2019

Aug 09, 2019
BUY
$61.87 - $69.38 $2.4 Million - $2.7 Million
38,865 Added 11.09%
389,260 $26.3 Million
Q1 2019

May 14, 2019
BUY
$62.53 - $70.05 $3.28 Million - $3.68 Million
52,519 Added 17.63%
350,395 $22.8 Million
Q4 2018

Feb 13, 2019
SELL
$60.54 - $79.0 $350,889 - $457,884
-5,796 Reduced 1.91%
297,876 $18.6 Million
Q3 2018

Nov 13, 2018
SELL
$71.28 - $78.92 $285,191 - $315,758
-4,001 Reduced 1.3%
303,672 $23.4 Million
Q2 2018

Aug 10, 2018
SELL
$64.88 - $75.68 $64,425 - $75,150
-993 Reduced 0.32%
307,673 $21.8 Million
Q1 2018

May 15, 2018
SELL
$72.84 - $88.8 $348,830 - $425,263
-4,789 Reduced 1.53%
308,666 $23.3 Million
Q4 2017

Feb 14, 2018
SELL
$71.15 - $83.52 $192,033 - $225,420
-2,699 Reduced 0.85%
313,455 $22.5 Million
Q3 2017

Nov 13, 2017
SELL
$72.11 - $85.47 $281,950 - $334,187
-3,910 Reduced 1.22%
316,154 $25.6 Million
Q2 2017

Aug 11, 2017
BUY
N/A
320,064
320,064 $22.7 Million

Others Institutions Holding GILD

# of Institutions
1,927
Shares Held
994M
Call Options Held
10.5M
Put Options Held
9.75M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Spears Abacus Advisors LLC Portfolio

Follow Spears Abacus Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spears Abacus Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Spears Abacus Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email